Choose conventional pharmacological agents if your primary therapeutic endpoint is transient, titration-dependent reduction of intraocular pressure (IOP); choose gene therapy when your mechanism focuses on sustained long-term IOP regulation or direct retinal ganglion cell neuroprotection that standard topicals cannot achieve.
Your strategy depends on four critical variables: therapeutic objective (whether targeting aqueous outflow resistance or downstream neuroprotective signaling pathways), durability requirements (avoiding daily dosing adherence limitations versus achieving stable multi-month expression), immunogenicity and safety risks (vector-mediated immune reactions and off-target ocular inflammation), and manufacturing and delivery complexity (subretinal or intracameral administration versus simple topical or intravitreal delivery).
Selecting conventional compounds yields established regulatory pathways and reversible dosing kinetics, but fails to prevent optic nerve degeneration caused by IOP-independent pathologies. Conversely, gene therapy offers single-dose durability and targeted cellular modulation, but risks irreversible vector-induced toxicity and severe immunogenicity if capsid biodistribution is uncharacterized.
Define your target cell population and disease mechanism in early proof-of-concept assays before finalizing your modality. Share your therapeutic target and study objectives to evaluate in vivo validation and safety screening options.